Empagliflozin vs Nivolumab

Empagliflozin vs Nivolumab: Overview

This comparison examines the pharmacological differences between Empagliflozin and Nivolumab.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7.

Molecular Weight: Empagliflozin — 450.9100 g/mol.

Type: Empagliflozin — Small molecule; Nivolumab — Antibody.